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Background: Atopic dermatitis (AD) is a multifactorial chronic inflammatory skin disease presenting with a
relapsing clinical pattern similar to chronic autoimmune disease. Several human transglutaminases have been
defined and keratinocyte transglutaminase (TG1) and epidermal transglutaminase (TG3) expressed in the epidermis
are associated with epidermal barrier dysfunction. Since impairments to the epidermal barrier represent an
important factor in AD, we hypothesized that IgA autoantibodies specific for TG1 (IgA-anti-TG1) and TG3
(IgA-anti-TG3) may affect AD development during childhood.
Methods: Active AD patients (n = 304), 28 patients with biopsy-confirmed coeliac disease (CD), 5 patients with
active AD and CD, and 55 control patients without CD and skin diseases were enrolled into the study. IgA-anti-TG1
and IgA-anti-TG3 reactivity was determined using an enzyme-linked immunosorbent assay. IgA-anti-TG2 were
defined using a fluoroenzyme immunoassay.
Results: IgA-anti-TG1 antibodies were found in 2% and IgA-anti-TG3 antibodies in 3% of patients with active AD.
Two out of the 5 patients with AD and concomitant CD had IgA-anti-TG1 and IgA-anti-TG2 antibodies. In CD
patients, 36% of individuals presented with elevated IgA-anti-TG1 antibodies and 18% presented with elevated
IgA-anti-TG3 antibodies and all CD patients presented with IgA-anti-TG2 antibodies (significantly different from AD
patients and controls, p < 0.05). In CD patients, IgA-anti-TG1 and/or IgA-anti-TG3 seropositivity tended to appear
concurrently, whereas only one patient with AD had both types of autoantibodies.
Conclusions: IgA-anti-TG1 and IgA-anti-TG3 seropositivity was rare in active AD but frequent in CD patients. The
level of circulating antibodies related to skin lesions could be studied by determining the levels of IgA-anti-TG1 and
IgA-anti-TG3 in skin biopsies of AD patients.
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Atopic dermatitis (AD) is a multifactorial, chronic, inflam-
matory skin disease characterized by intense pruritus and
relapsing eczema. At least 4 different factors are involved
in AD progression: congenital skin barrier defects, allergy,
microbial colonization, and/or autoimmunity [1]. Almost
2/3 of children that present with the clinical phenotype of
AD have no identifiable allergen-specific sensitization. On* Correspondence: raivo.uibo@ut.ee
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unless otherwise stated.the other hand, AD presents as a relapsing-remitting dis-
ease similar to that of chronic autoimmune diseases [2].
However, the role of autoimmunity in the development of
AD skin lesions is not well defined despite extensive stud-
ies focusing on structural changes to the epidermis and
immune dysregulation [3-6].
Recent studies have suggested a role for epidermal
transglutaminases that can affect epidermal barrier dys-
function and present at higher concentrations in the
skin of AD patients, especially in skin lesions, and dur-
ing skin barrier repair [7-9]. Transglutaminases are a
family of calcium-dependent enzymes important to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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organization and apoptosis. Several transglutaminases
have been described in humans and 4 localize to the
epidermis [7,10]. Keratinocyte transglutaminase (TG1)
and epidermal transglutaminase (TG3) are expressed in
the spinous and granular layers of the epidermis [10],
while tissue transglutaminase (TG2) is widely expressed
in various tissues, including the gut epithelium. How-
ever, their expression in the epidermis can be demonstrated
only under specific conditions [10,11]. TG2 was identified
in 1997 as an autoantigen in coeliac disease (CD), an im-
mune mediated gluten enteropathy with a wide range of
clinical presentations [12]. IgA autoantibodies specific for
TG2 (IgA-anti-TG2) are often found in patients with CD
and can be found in some dermatitis herpetiformis (DH)
patients. Despite the diagnostic sensitivity of IgA-anti-TG2
for CD, children < 24 months of age have been shown to
have a decreased ability to produce antibodies to TG2 [13].
Instead, these patients may have antibodies against deami-
dated gliadin peptides (DGP), another type of autoantibody
associated with CD. These antibodies develop following the
deamidation of the cereal protein component gliadin by
TG2 in the gut mucosa [14]. Moreover, in patients with
DH, IgA autoantibodies develop against TG3, and precipi-
tate as immune complexes in the papillary dermis thereby
impacting skin lesion pathogenesis in DH patients [15,16].
Mutations in the TG1 coding gene have been reported to
be deficient in lamellar ichthyosis, a disease with severely
impaired epidermal barriers [10].
Since dysfunction of the epidermal barrier and auto-
immunity play important roles in the pathogenesis of AD,
we hypothesized that IgA autoantibodies specific for TG1
(IgA-anti-TG1) and TG3 (IgA-anti-TG3) may play a role
in childhood AD development. To test this hypothesis we
measured serum IgA-anti-TG1, IgA-anti-TG3, and IgA-
anti-TG2 in children with active AD, in children with ac-
tive AD and concomitant CD, in children with known CD,




We tested 392 serum samples obtained from four groups
of children: 304 patients with active AD (mean age
5.5 years, 174 boys), 5 patients with active AD and con-
comitant CD (mean age 5.6 years, 1 boy), 28 patients with
only CD (mean age 6.2 years, 10 boys), and 55 control pa-
tients with normal small bowel mucosa without skin dis-
eases (mean age 9.2 years, 27 boys). Patients with active
AD, patients with active AD and concomitant CD, and
children with normal small bowel mucosa were recruited
from the Tallinn Children’s Hospital. Children with CD
were studied either at Tallinn Children’s Hospital or at the
Children’s Clinic of Tartu University Hospital. Patientswith normal small bowel mucosa and CD were identi-
fied following histological analysis of small bowel mu-
cosa biopsy specimens and characterized according to
the European Society for Pediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) diagnostic cri-
teria [17] taking into account Marsh classification [18].
The clinical presentation of CD was defined as classical,
atypical gastrointestinal, extraintestinal, or silent type
[14,19]. No patients in the study were on a gluten-free
diet or systemic immunomodulatory treatment.
Written informed consent was obtained from all study
participants or their parents or legal guardians. The study
was conducted in accordance with the ethical guidelines
established by the Declaration of Helsinki and approved
by the Ethics Review Committee on Human Research of
the University of Tartu, Estonia.
Total IgA, IgA-anti-TG2, and IgA-anti-DGP
To exclude an IgA deficiency, total serum IgA was deter-
mined for all samples using a chemiluminescence assay
(Roche Diagnostics, Burgess Hill, England) and the results
were compared to age-specific reference values. The IgA-
anti-TG2 and IgA-anti-DGP responses were measured
using a fluoroenzyme immunoassay using the ImmunoCAP
EliA Celikey system (Thermo Fisher Scientific, Uppsala,
Sweden). According to the manufacturer’s recommenda-
tions, IgA-anti-TG2 and IgA-anti-DGP values of 10 EliA
U/ml or higher were considered positive, and values lower
than 7 EliA U/ml were considered negative. Borderline
values (between 7 and 10 EliA U/ml) were considered nega-
tive for the purposes of carrying out statistical analysis.
IgA-anti-TG1 and IgA-anti-TG3
The IgA-anti-TG1 and IgA-anti-TG3 were measured by
an enzyme-linked immunosorbent assay as described earl-
ier (ELISA) [20] using recombinant TG1 and TG3 as tar-
get antigens (Zedira GmbH, Darmstadt, Germany). Briefly,
universal binding 96-well microtiter plates (Thermo Fisher
Scientific OY, Vantaa, Finland) were coated with 0.5 μg
TG1 or TG3 per well overnight at 4°C. After washing and
rinsing of the wells with 5% sucrose, plates were dried and
kept at 4°C until use. Serum samples were diluted 1:100 in
TBS-T buffer (25 mM Tris–HCl, 150 mM NaCl, 0.1%
Tween 20, pH 7.4) and incubated in duplicate wells for
1 h at room temperature. After washing with TBS-T 5
times, wells were incubated for 30 min with a 1:1000 dilu-
tion (in TBS-T) of alkaline phosphatase (AP)-conjugated
goat anti-human IgA (Invitrogen Corporation, Camarillo,
USA). Reactivity was visualized by developing using the
substrate 4-p-nitrophenyl phosphate for 30 min and meas-
uring absorbance values at 405 nm with a 492 nm subtrac-
tion. Antibody levels were expressed in arbitrary units
(AU) as percentages of the reference serum OD values.
The assay cut-off values for IgA-anti-TG1 and IgA-anti-
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2SD in the control subjects, which yielded IgA-anti-
TG1 values higher than 37.3 AU and IgA-anti-TG3
values higher than 48.8.
Statistical analysis
The data were expressed as absolute numbers or propor-
tions for categorical variables and as means for continuous
variables. The diagnostic performance of both assays in
terms of sensitivity and specificity, expressed as a percent-
age, was calculated based on the cut-off values described
above. For statistical analyses, the R software for Windows
(The R Foundation for Statistical Computing, Vienna,
Austria) and the MedCalc statistical software (MedCalc
Software, Mariakerke, Belgium) were used. Differences
between subgroups were analyzed using the Fisher’s
exact test or the Wilcoxon rank sum test as appropriate.
A p-value ≤0.05 was considered significant.
Results
Determination of total IgA, IgA-anti-TG2,
and IgA-anti-DGP
Seven (2%) of the AD patients and three (5%) control
patients were IgA deficient and therefore excluded from
further antibody and statistical analysis. Differences in
IgA deficiency rates between these groups were not sta-
tistically significant.
Seropositivity rates of the different study groups are
shown in Table 1. No patients in the AD group presented
with IgA-anti-TG2 and 7 patients (2%) had slight IgA-
anti-DGP reactivity (all were >2 years of age and none
were seropositive for other markers). Of the 5 AD patientsTable 1 Seropositivity rates of the different patient groups*
IgA-anti-TG1 IgA-anti-TG2
+ - + -
AD 6 291 0 297
(n = 297) (2%) (98%) (100%)
AD + CD 2 3 4 1
(n = 5) (40%) (60%) (80%) (20%)
CD 10 18 27 1
(n = 28) (36%) (64%) (96%) (4%)
Controls 2 50 1 51
(n = 52) (4%) (96%) (2%) (98%)
AD vs controls p = 0.340 AD vs controls p = 0.14
AD vs CD p = 0** AD vs CD p = 0
AD vs ADCD p = 0.006 AD vs ADCD p = 0
ADCD vs controls p = 0.035 ADCD vs controls p < 0.00
ADCD vs CD p = 1 ADCD vs CD p = 0.284
CD vs controls p < 0.005 CD vs controls p = 0
*Children with low serum IgA were excluded.
**p values marked in bold are statistically significant.with concomitant CD, 4 had IgA-anti-TG2 and 3 had IgA-
anti-DGP antibodies. In CD patients IgA-anti-TG2 was
identified in 27 (96%) and IgA-anti-DGP in 24 (86%, all
IgA-anti-TG2 positive). In the control group, only 1 patient
presented with borderline IgA-anti-TG2 values without any
accompanying seropositivity. Elevated IgA-anti-DGP
values were found in the sera of 2 control group pa-
tients, both <2 years of age and without other detect-
able autoantibodies. No changes to the small intestine
mucosa were identified in these patients.
IgA-anti-TG1
IgA-anti-TG1 antibodies were found in all patient
groups (Table 1). Six patients with AD (2%) and 2 con-
trol patients (4%) had elevated IgA-anti-TG1, but were
IgA-anti-TG2 negative. Two patients with AD also pre-
senting with CD had IgA-anti-TG1 responses and both
were also positive for IgA-anti-TG2 and IgA-anti-DGP.
Ten patients (36%) with CD had IgA-anti-TG1 anti-
bodies and all were IgA-anti-TG2 positive. The IgA-anti-
TG1 positive CD patients were also IgA-anti-DGP posi-
tive except for 1 patient with borderline IgA-anti-DGP
values but with marked IgA-anti-TG2 responses.
IgA-anti-TG3
IgA-anti-TG3 antibodies were found in all patient groups
except patients with concomitant AD and CD (Table 1). El-
evated IgA-anti-TG3 responses were detected in 9 patients
(3%) with AD and in 3 control patients (4%), none of them
presented with elevated IgA-anti-TG2 levels. Five patients
(18%) with CD had elevated IgA-anti-TG3 response, all of
them were IgA-anti-TG2 and IgA-anti-DGP positive.IgA-anti-TG3 IgA-anti-DGP
+ - + -
9 288 7 290
(3%) (97%) (2%) (98%)
0 5 3 2
(100%) (60%) (40%)
5 23 24 4
(18%) (82%) (86%) (14%)
2 50 2 50
(4%) (96%) (4%) (96%)
AD vs controls p = 0.671 AD vs controls p = 0.628
AD vs CD p < 0.005 AD vs CD p = 0
AD vs ADCD p = 1 AD vs ADCD p < 0.005
5 ADCD vs controls p = 1 ADCD vs controls p < 0.005
ADCD vs CD p = 0.569 ADCD vs CD p = 0.216
CD vs controls p = 0.048 CD vs controls p = 0
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Among the AD patients the IgA-anti-TG1 and IgA-anti-
TG3 responses were as prevalent as responses observed in
the control group. IgA-anti-TG1 and IgA-anti-TG3 re-
sponses were more common among CD patients than
among controls or AD patients (p < 0.05). Among the CD
patients, both the mean levels of IgA-anti-TG1 and IgA-
anti-TG3 antibodies were higher compared to levels ob-
served in AD patients or in the control group (p < 0.05)
(Figure 1). In AD patients with concomitant CD, IgA-anti-
TG1 responses were as prevalent as in the CD patients
but more common compared to controls (p < 0.05) or AD
patients (p < 0.005), indicating that IgA-anti-TG1 and IgA-
anti-TG3 responses were associated with CD and not AD.
Comparisons between all seropositive cases from the
different patient groups revealed that only 1 patient with
active AD had both elevated IgA-anti-TG1 and IgA-anti-
TG3 antibody levels, however, patients presenting with
CD or with AD and concomitant CD tended to be sero-
positive for IgA-anti-TG1 and/or IgA-anti-TG3 together
with IgA-anti-TG2 and IgA-anti-DGP seropositivity (see
Additional file 1: Table S1 for more details).
Elevated IgA-anti-TG1 and IgA-anti-TG3 levels were
also found in 3 control patients. One patient presented
with long-lasting diarrhoea and elevated levels of both
antibodies and was later diagnosed with cystic fibrosis.
The other 2 patients were either IgA-anti-TG1 or IgA-
anti-TG3 seropositive. However, these 2 patients pre-
sented with acute gastritis resulting from a Helicobacter
pylori infection that may be a predisposing factor for de-
veloping IgA-anti-TG1 and/or IgA-anti-TG3 responses.
When comparing IgA-anti-TG1, IgA-anti-TG2, and IgA-
anti-TG3 responses using the Spearman’s rank correlation,
a statistically significant correlation was noted betweenFigure 1 IgA-anti-TG1 (A) and IgA-anti-TG3 (B) values in the different
*Horizontal line - reference value based on the mean + 2SD of the controlIgA-anti-TG1 and IgA-anti-TG2 response (r = 0.51), IgA-
anti-TG3 and IgA-anti-TG2 response (r = 0.44) and be-
tween the IgA-anti-TG1 and IgA-anti-TG3 assay response
(r = 0.70). When comparing antibody responses in CD pa-
tients, a statistically significant correlation was noted be-
tween the IgA-anti-TG1 and IgA-anti-TG3 response (r =
0.64) and between the IgA-anti-TG1 and IgA-anti-DGP
assay response (r = 0.48) (Figure 2).
Discussion
In recent years, characterization of skin-related immune
processes and involvement of autoimmune reactions associ-
ated with the pathogenesis of AD have received much atten-
tion [6]. In the present study we determined whether TG1
and TG3 (enzymes that maintain skin barrier integrity)
could be targets for IgA autoantibodies in patients with AD.
We found no increases in IgA-anti-TG1 and IgA-anti-
TG3 antibodies, nor in the CD biomarkers IgA-anti-TG2
and IgA-anti-DGP among AD patients compared to the
control group. In the group of AD patients with slightly
elevated IgA-anti-DGP the antibody concentration was
relatively low compared to the corresponding concen-
trations in biopsy-confirmed CD patients, therefore, a
longitudinal clinical follow-up can be recommended in
these children to confirm persistent seropositivity.
Our findings suggested that IgA antibodies specific for
TG isoenzymes (expressed in the dermis) are not charac-
teristic of AD. However, the levels of IgA-anti-TG1 and
IgA-anti-TG3 were significantly higher in CD patients
compared with patients in the other groups. IgA-anti-
TG3 antibodies were found in 18% of CD patients in
concordance with earlier studies where IgA-anti-TG3
antibodies were detected in 11-33% of untreated CD pa-
tients [21,22]. In the CD group, IgA-anti-TG1 and IgA-patient groups. AD, atopic dermatitis; CD, coeliac disease.
subjects.
Figure 2 Correlation plots for IgA-anti-TG1, IgA-anti-TG2, IgA-anti-TG3 and IgA-anti-DGP in patients with CD.
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seropositive CD patients also had elevated IgA-anti-
TG2 responses. Considering IgA-anti-TG3 as a marker
for DH, the higher prevalence of IgA-anti-TG3 in CD
patients may indicate the possible clinical development
of the CD skin phenotype later in life [16,23].
Somewhat surprisingly, IgA-anti-TG1 responses were
detected frequently (36%) in CD patient sera. This ob-
servation had not previously been described and is at
this time difficult to explain. However, it clearly shows
that IgA reactivity against other TG family members
needs to be further studied in patients with CD. For ex-
ample, antibodies against neuronal transglutaminase
(TG6) have been described in a subgroup of patients
with gluten-sensitive cerebellar ataxia [24].
The identification of autoantibodies against different
types of TG does not rule out the potential for cross-reactivity between TGs. When comparing IgA-anti-TG1,
IgA-anti-TG2, and IgA-anti-TG3 levels between the study
groups we identified a moderate but statistically sig-
nificant correlation between the IgA-anti-TG1 and
IgA-anti-TG2 assays and between results of the IgA-
anti-TG3 and IgA-anti-TG2 assays, indicating possible
cross-reactivity between the tested TGs. However, this
potential cross-reactivity does not conceal specific re-
activity against various TGs that may exist since none
of the controls or AD patients had significantly ele-
vated IgA-anti-TG1 and/or IgA-anti-TG3 responses in
association with IgA-anti-TG2 responses.
Data presented in this report support a role for
antigen-specific IgA reactivity against dermal TGs in a
minority of children. Whether these antibodies have a
prognostic value in the diagnosis of autoimmune dis-
eases will require further studies.
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Based on experiments designed to evaluate the levels of
antibodies against TG1, TG2, and TG3, no significant asso-
ciation was found between any of these autoantibodies and
AD. On the contrary, we showed that IgA-anti-TG1 and
IgA-anti-TG3 responses occurred frequently in CD patients
suggesting that circulating antibodies to skin transglutami-
nases TG1 and TG3 were not related to AD. Further
research should focus on measuring IgA-anti-TG1 and
IgA-anti-TG3 responses in skin biopsies from AD patients.
Additional file
Additional file 1: Table S1. Detailed characterization of IgA-anti-TG1
and IgA-anti-TG3 seropositive cases.
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